RhoVac recruits Professor Emeritus Per-Anders Abrahamsson and Professor Klaus Brasso to its scientific advice board

Report this content

RhoVac AB ("RhoVac") is in the final development phase under its own direction with the clinical BraVac study and it intends to intensify its partnership discussions. Pertaining to this, RhoVac announces the recruitment of two very prominent prostate cancer experts, Professor Emeritus Per-Anders Abrahamsson at Lund University and Professor Klaus Brasso at the University of Copenhagen, to the company's Scientific Advisory Board.

Per-Anders-Abrahamsson is former Head of Operations at the Urological Clinic, Skåne University Hospital SUS and Research Group Head at the Faculty of Medicine, Department of Clinical Sciences, at Lund University. In these capacities, during the years 1998–2015, he led the development of the urology operations in Malmö and Lund to become one of Sweden’s finest. Professor Abrahamsson has published over 300 scientific articles and authored 80 book chapters in urology, focusing on diseases of the prostate. He is an adviser to the editors of a number of scientific journals and is often invited as a speaker at international congresses, appearances that have been awarded with numerous awards. Professor Abrahamsson has also been Secretary General of the European Association of Urology (EAU), and is an adjunct professor at the Department of Urology at the University of Rochester Medical Center, New York, USA, and at the Russian Institute of Urology, Moscow, Russia. Professor Abrahamsson is currently Chief Physician at the Peritus Clinic at Medicon Village in Lund.

Klaus Brasso, graduated in 1985 at the University of Copenhagen, Denmark, and in 2000 he obtained his doctorate at the same university. Professor Brasso is active in the Department of Clinical Medicine at the University of Copenhagen and is also a member of the management of the Copenhagen Prostate Cancer Center (CPC) at Rigshospitalet in Copenhagen. CPC is a center for most research activities on prostate cancer screening and treatment - from basic prostate cancer research, to the testing of new drugs and treatment methods. Professor Brasso  who has published more than 200 scientific articles, has also a long and solid experience in clinical studies in urology, from clinical phase I to phase III studies, and he is the Principle Investigator in RhoVac's ongoing clinical phase IIb study in prostate cancer (BraVac) which is expected to recruit 180 patients in Europe and the United States.

CEO Anders Månsson comments: “I am very pleased that we have succeeded in recruiting such prominent names in international urology as Professors Abrahamsson and Brasso. In addition to the scientific advice they can offer, this recruitment also generates great credibility and attention around our RV001 project and the company, and that will benefit our partnering process going forward.”

For further information, please contact:

Anders Månsson – CEO, RhoVac AB

Phone number: +46 73-751 72 78

E-mail: info@rhovac.com

This information is such that RhoVac AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on the 11th June 2020.

About RhoVac AB

RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has passed the early stages of development. In 2018, the first clinical trial (phase I / II) was completed in prostate cancer, demonstrating that RV001 has good safety and is well tolerated, and that the drug provides the expected immune response that will exert its effect on the cancer cells. The strong immune response has also been shown to last over time. Therefore, RhoVac is launching a clinical phase IIb trial that will include at least 175 prostate cancer patients. The study is designed to show, with statistical significance, the effect of RV001 in preventing disease progression in prostate cancer after surgery or radiation to the primary tumor. RhoVac is listed on Spotlight, Sweden, a Multilateral Trading Facility (MTF) since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com


Documents & Links